KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent TaxesDividends payablesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Merck (MRK) Short-term Investments (2016 - 2025)

Merck (MRK) has disclosed Short-term Investments for 16 consecutive years, with $615.0 million as the latest value for Q2 2025.

  • On a quarterly basis, Short-term Investments changed N/A to $615.0 million in Q2 2025 year-over-year; TTM through Jun 2025 was $615.0 million, a N/A change, with the full-year FY2024 number at $447.0 million, up 77.38% from a year prior.
  • Short-term Investments was $615.0 million for Q2 2025 at Merck, up from $447.0 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $615.0 million in Q2 2025 to a low of $252.0 million in Q4 2023.
  • A 4-year average of $453.0 million and a median of $472.5 million in 2022 define the central range for Short-term Investments.
  • Peak YoY movement for Short-term Investments: tumbled 49.4% in 2023, then skyrocketed 77.38% in 2024.
  • Merck's Short-term Investments stood at $498.0 million in 2022, then plummeted by 49.4% to $252.0 million in 2023, then surged by 77.38% to $447.0 million in 2024, then surged by 37.58% to $615.0 million in 2025.
  • Per Business Quant, the three most recent readings for MRK's Short-term Investments are $615.0 million (Q2 2025), $447.0 million (Q4 2024), and $252.0 million (Q4 2023).